eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | chronic myeloproliferative disease |
| Comorbidity | C0836924|thrombocytosis |
| Sentences | 9 |
| PubMedID- 22084665 | Clonal thrombocytosis associated with the myeloproliferative neoplasms, especially essential thrombocythemia and polycythemia vera, carries a unique prognostic profile, with a markedly increased risk of thrombosis. |
| PubMedID- 19958208 | Conclusions: among all indices, the pdw has been receiving attention due to its usefulness for distinguishing between reactive thrombocytosis and thrombocytosis associated with myeloproliferative disorder. |
| PubMedID- 24944610 | Primary thrombocytosis is a type of myeloproliferative disease with 50–70% of patients exhibiting mutations in the jak2v617f gene and plt levels >600×109/l and even up to 1,000×109/l (1). |
| PubMedID- 23238075 | It is uncertain whether thrombocytosis without underlying myeloproliferative diseases is associated with an increased risk of acute pulmonary embolism (pe). |
| PubMedID- 24155890 | 82 patients (male/female: 48/34, mean age: 62.8 years, range: 28–82) were recruited: 17 suffered from aml (acute myeloid leukemia) (11 de novo and 6 after transformation of myelodysplastic syndrome), 4 from all (acute lymphoblastic leukemia), 15 from cml (chronic myeloid leukemia) in chronic phase, 26 from jak2-v617f-positive mpns (myeloproliferative neoplasms) (including 16 with essential thrombocytosis, 5 with polycythemia vera and 5 with idiopathic myelofibrosis), 4 from jak2-v617f-negative mpns (2 with essential thrombocythemia and 2 with idiopathic myelofibrosis) and 16 from cll. |
| PubMedID- 21312258 | myeloproliferative disorders may present with thrombocytosis and/or leukocytosis with symptoms ranging from minor to life-threatening. |
| PubMedID- 20586925 | Background: anagrelide is a selective inhibitor of megakaryocytopoiesis used to treat thrombocytosis in patients with chronic myeloproliferative disorders. |
| PubMedID- 19643476 | Mpl gene mutations seem to be associated with thrombocytosis, regardless of the type of myeloproliferative neoplasm. |
| PubMedID- 22381681 | This study provides new insights into the mechanisms underlying lbh589-induced thrombocytopenia and provides a rationale for using tubulin as a target for selective histone deacetylase inhibitor therapies to treat thrombocytosis in patients with myeloproliferative neoplasms. |
Page: 1